Clinical Conversations

September 9th, 2014

Podcast 174: PARADIGM and Heart Failure

The PARADIGM-HF trial of LCZ696 — a novel compound that both blocks the renin-angiotensin system with an ARB component and blocks neprilysin’s degradation of natriuretic peptides — increased survival in heart failure by some 20% relative to enalapril. It seems to be a big deal, and the trial’s two principal authors have agreed to talk […]

---

December 3rd, 2010

Podcast 110: ARBs (and anti-hypertensives, generally) pose no measurable cancer risk, meta-analysis shows.

This week’s guest, Dr. Sripal Bangalore, finds no evidence that use of the standard anti-hypertensive drugs increases risks for cancer. His meta-analysis did find, however, an indication that ARBs and ACE inhibitors, when used in combination, increase risks modestly. Even with the short follow-up, Bangalore says clinicians should find reassurance in the results. Listen in. Interview-related links: Physician’s […]

---

July 10th, 2009

Podcast 49: Three RASS Study researchers discuss their findings on the lack of benefit of renin-angiotensin blockade in the primary prevention of diabetic nephropathy in Type 1 diabetes.

We talk with Drs. Michael Mauer, Ronald Klein, and Bernard Zinman about their paper in the July 2 New England Journal of Medicine reporting on the RASS study (Renin-Angiotensin System Study). They found that blockade of the renin-angiotensin system was not effective in the primary prevention of diabetic nephropathy in Type 1 diabetes. This week’s […]

---

July 2nd, 2009

Podcast 48: A conversation with Les Irwig, which your bone scanner won’t like to hear.

Scanning patients on bisphosphonates within the first 3 years of therapy is just wasted effort, and may even be misleading clinically. That’s what researchers conclude after reanalysis of FIT trial data on some 6500 women taking either alendronate or placebo. Prof. Les Irwig of the University of Sydney talks about his team’s findings and what […]

---